HF
RNAC icon

HRT Financial’s Cartesian Therapeutics RNAC Stock Holding History

HRT Financial’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-502
Closed -$10K – 2972
2023
Q4 		$10K Buy
+502
New +$15K ﹤0.01% 2085
2023
Q2 		– Sell
-12,766
Closed -$532K – 3148
2023
Q1 		$532K Buy
+12,766
New +$600K 0.01% 1328
2022
Q3 		– Sell
-4,721
Closed -$185K – 3393
2022
Q2 		$185K Buy
4,721
+4,308
+1,043% +$128K ﹤0.01% 2271
2022
Q1 		$15K Sell
413
-4,532
-92% -$283K ﹤0.01% 2864
2021
Q4 		$483K Buy
+4,945
New +$532K ﹤0.01% 1922
2019
Q4 		– Sell
-451
Closed -$23K – 1560
2019
Q3 		$23K Buy
+451
New +$24K ﹤0.01% 1333

Other funds holding RNAC

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HRT Financial's RNAC Position: Q1 2024 in Review

HRT Financial sold out of Cartesian Therapeutics (RNAC) in Q1 2024, closing a stake of 502 shares — an estimated $10K sold.

HRT Financial first reported a position in RNAC in Q3 2019 and held it in 6 quarters. The position peaked at $532K in Q1 2023. 69 funds tracked by Wall St. Rank hold RNAC as of Q1 2024.

  • HRT Financial reported no remaining Cartesian Therapeutics position as of Q1 2024 after selling out during the quarter.
  • HRT Financial sold 502 Cartesian Therapeutics shares in Q1 2024, an estimated $10K.
  • HRT Financial first reported a position in Cartesian Therapeutics in Q3 2019 and held it in 6 quarters.
  • HRT Financial's Cartesian Therapeutics position peaked at $532K in Q1 2023.
  • 69 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2024.

Based on HRT Financial's 13F filing for Q1 2024, filed 13 May 2024.